Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx to develop obesity and diabetes targets
Decreased insulin activity is known to contribute to type 2 diabetes and other complications such as obesity, and these targets have demonstrated the ability to regulate insulin activity
Decreased insulin activity is known to contribute to type 2 diabetes and other complications such as obesity, and these targets have demonstrated the ability to regulate insulin activity
The deal provides Amgen with full ownership of panitumumab, a potential blockbuster anticancer compound that the companies have been developing together. Shareholders of Abgenix will receive $22.50 in
As a result of NKS104’s disappointing performance, Novartis intends to book a $266 million charge in the fourth quarter of 2005 to fully write off the remaining value
The company anticipates completing its pivotal phase III trial for Pennsaid by the end of 2005. Preliminary results from the trial are likely to be disclosed in January
Set for UK release in January 2006, Sirco is the first heart health product to contain the patented ‘Fruitflow’ technology. Provexis said Fruitflow has been developed to help
CollaGenex will make an initial payment of $750,000 for 51% of the shares of SansRosa. The remaining shares will be purchased upon the achievement of various milestones. If
Understanding the nature of cancer stem cells could result in new therapies that specifically target those cells which are thought to be the driving force of tumor progression.
The review of the flu vaccine came after the deaths of 12 children in Japan who had been taking Tamiflu. The European Medicines Agency ruled the treatment could
Men with prostrate cancer on androgen deprivation therapy (ADT) experienced highly statistically significant increases in bone mineral density (BMD) after one year of treatment with Acapodene (toremifene citrate).
The recommendation is based on data presented from phase III clinical trials that evaluated the effects of the drug in 70,000 infants. The FDA will now consider the